Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N9F7
UPID:
GDPD1_HUMAN
Alternative names:
Glycerophosphodiester phosphodiesterase 4; Glycerophosphodiester phosphodiesterase domain-containing protein 1
Alternative UPACC:
Q8N9F7; A8W735; Q56VR1; Q8N4E3
Background:
Lysophospholipase D GDPD1, also known as Glycerophosphodiester phosphodiesterase 4, plays a crucial role in lipid metabolism by hydrolyzing lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and corresponding amines. It shows a preference for substrates like lyso-PAF, lyso-PE, and lyso-PC, and is involved in bioactive N-acylethanolamine biosynthesis. This enzyme's specificity towards certain phospholipids underlines its importance in cellular lipid remodeling and signaling.
Therapeutic significance:
Understanding the role of Lysophospholipase D GDPD1 could open doors to potential therapeutic strategies.